BTIG analyst Julian Harrison maintained a Buy rating on VYNE Therapeutics yesterday and set a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison has given his Buy rating due to a combination of factors that highlight the promising outlook for VYNE Therapeutics. The Phase 2b trial of repibresib, a topical BET inhibitor for treating vitiligo, shows significant potential, with the market for vitiligo treatments expected to grow. The upcoming topline data from this trial is anticipated to position repibresib as a preferred first-line treatment option due to its potentially superior efficacy and cleaner safety profile compared to the currently approved therapy, Opzelura.
Moreover, previous trial results suggest that repibresib may offer greater efficacy at an earlier stage, and the ongoing trial’s longer treatment course and higher dosage could further enhance its effectiveness. Additionally, the patient population in the current trial is considered less challenging to treat, which could mean the efficacy of repibresib is understated. The management’s confidence in the safety profile of repibresib, combined with positive feedback from key opinion leaders, supports the potential for significant market share capture. These factors collectively underpin the Buy rating for VYNE Therapeutics.
According to TipRanks, Harrison is a 4-star analyst with an average return of 4.8% and a 46.76% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Theravance Biopharma, and Nektar Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.